Denmark: Adcendo appoints Michael Pehl as CEO as company reaches inflection point

Michael Pehl has been appointed CEO of Adcendo, a Copenhagen-based biotech company dedicated to developing antibody-drug conjugates (ADCs) for the treatment of cancer. Henrik Stage, co-founder of Adcendo, will move to the role of CFO. Pehl has over 25 years of international biotechnology and oncology experience in both the US and Europe. He joins Adcendo…

You must be a HMI Subscriber to view this content.

Subscribe Now »